|
ELIL·Direxion Daily LLY Bull 2X Shares
$29.93
+2.04 (+7.31%)
High
$30.27
Open
$28.34
Net Assets
$17M
52W High
—
Low
$28.10
P. Close
$29.93
52W Low
—
Div. Yield
1.44%
Next Ex-Div
~Dec 22
Technical Score (1D)
76
BULLISH
News Sentiment
45
MIXED
Sentiment gathered from recent headlines
ETF: ELIL
Direxion Daily LLY Bull 2X Shares (ELIL) is a leveraged ETF, designed to deliver two times the daily performance of Eli Lilly and Company (LLY). This structure amplifies both gains and losses, making it a high-risk, high-reward investment. The fund's non-diversified nature means its performance is heavily reliant on the price movements of a single stock, LLY, increasing its volatility.
ELIL's investment strategy focuses on providing leveraged exposure to LLY through a combination of securities and financial instruments. Given its leveraged nature and single-stock focus, ELIL is best suited for short-term, tactical trading strategies rather than long-term investment portfolios. Careful monitoring and risk management are crucial when considering this ETF.
ELIL aims to provide 2x leveraged exposure to the daily performance of LLY. This means that for every 1% move in LLY's price, ELIL is designed to move by 2%. This leverage magnifies both gains and losses, increasing the fund's volatility.
The fund achieves its leveraged exposure through a combination of LLY securities and financial instruments like swaps and options. This approach allows ELIL to maintain its leveraged position without directly holding a large number of LLY shares.
This is especially true during periods of high volatility or sideways market movement.
ELIL's portfolio is highly concentrated, with 100% of its holdings in Eli Lilly and Company (LLY). This lack of diversification means the fund's performance is directly tied to the performance of a single stock.
The fund's non-diversified structure amplifies both the potential rewards and risks associated with investing in ELIL. Any adverse news or market downturn affecting LLY will have a significant impact on the fund's value.
ELIL is a leveraged ETF, designed to provide a multiple of the daily returns of its underlying asset. This structure makes it suitable for short-term trading strategies rather than long-term investing.
The fund's structure involves the use of financial instruments like swaps and options to achieve its leveraged exposure. This can introduce additional complexities and risks compared to traditional ETFs.
The daily reset of the leverage factor means that the fund's performance over longer periods may deviate significantly from the expected multiple of the underlying asset's returns.
ELIL's leveraged nature and single-stock focus make it suitable for tactical trading strategies.
The fund's liquidity and trading volume are important factors to consider. High trading volume can help reduce the bid-ask spread and minimize trading costs.
Due to its leveraged nature, ELIL is not suitable for buy-and-hold investors. It is designed for short-term trading and requires active management.
ELIL is best suited for a small, tactical allocation within a broader portfolio. Its high volatility and leveraged nature make it unsuitable as a core holding.
Investors can use ELIL to express a short-term bullish view on LLY or to hedge against potential declines in the stock.
Due to its high risk profile, ELIL should be used cautiously and only by investors with a high risk tolerance and a thorough understanding of leveraged ETFs.
Given its leveraged nature and single-stock focus, ELIL is best suited for short-term trading strategies. Due to its high volatility, ELIL should be used for tactical bets, and position sizes should be carefully managed to limit potential losses. Regular monitoring and active management are crucial when holding ELIL.
ELIL seeks to deliver leveraged exposure to Eli Lilly (LLY) stock, amplifying its daily price movements. This strategy makes ELIL highly sensitive to the specific factors driving LLY's performance.
The success of LLY's drug pipeline, especially new drug approvals and clinical trial results, directly impacts ELIL's performance. Positive developments, such as FDA approvals or positive trial data, can lead to significant price increases for LLY.
This translates directly to ELIL, as its 2x leverage magnifies these gains. Conversely, setbacks in the pipeline can lead to amplified losses for the ETF.
ELIL's 2x leverage magnifies both gains and losses compared to the daily performance of LLY. This means that even small price movements in LLY can result in substantial percentage changes in ELIL's value.
Investors must understand that this leverage increases the risk of significant losses, especially during periods of market volatility or when LLY's price moves against the investor's position.
Broader sentiment towards the pharmaceutical sector influences LLY's valuation, which in turn affects ELIL. Positive news or trends in the pharma industry, such as increased R&D spending or favorable regulatory changes, can boost investor confidence in LLY.
As ELIL holds 100% of its assets in LLY, sector-wide headwinds, such as increased competition or negative drug pricing news, can weigh heavily on the ETF's returns.
Key insight: ELIL's performance hinges on the specific catalysts affecting LLY and the broader pharma sector, amplified by its leveraged structure.
ELIL seeks to deliver leveraged exposure to Eli Lilly and Company (LLY).
Daily Leverage Factor: This metric reflects the fund's objective to provide 2x the daily return of LLY. Due to compounding, returns over periods longer than one day can deviate from 2x LLY's performance. Monitor this factor to understand the fund's sensitivity to daily price movements in LLY.
LLY Holdings Weight: This metric shows the fund's concentration in Eli Lilly and Company (LLY), currently at 100%. High concentration amplifies the impact of LLY's price fluctuations on ELIL's performance. Changes in this weight would signal a shift in the fund's exposure.
Trading Volume & Spread: Measures the fund's liquidity and trading costs. Wider spreads and lower volume can increase trading costs, especially during volatile periods. Monitor these to gauge the ease and cost of entering or exiting ELIL positions.
52-Week High/Low: This metric provides context for the fund's current price relative to its recent trading range. A price near the 52-week high may indicate strong upward momentum, while a price near the 52-week low may signal weakness. Use this to assess the fund's recent performance and potential risk.
Expense Ratio: The expense ratio represents the annual cost of owning the fund. Higher expense ratios can erode returns over time. Monitor this to understand the fund's fee drag on performance.)
Volatility Regime: Assesses the fund's sensitivity to market volatility. Leveraged ETFs like ELIL amplify both gains and losses. Monitor market volatility to understand the potential impact on ELIL's returns. Increased volatility can lead to more significant price swings.
ELIL seeks to deliver 2x leveraged exposure to Eli Lilly and Company (LLY). This strategy amplifies both gains and losses, and the fund's concentrated holdings in a single stock create significant risk.
